Is elevated SUA associated with a worse outcome in young Chinese patients with acute cerebral ischemic stroke? by Zhang, Bin et al.
RESEARCH ARTICLE Open Access
Is elevated SUA associated with a worse outcome
in young Chinese patients with acute cerebral
ischemic stroke?
Bin Zhang
1,2, Cong Gao
1,2*, Ning Yang
4, WeiZhi Zhang
3, XingWang Song
1,2, JianRui Yin
1,2, ShuXiang Pu
1,2,
YongHong Yi
1,2, QingChun Gao
1,2
Abstract
Background: Elevated serum uric acid (SUA) levels can enhance its antioxidant prosperities and reduce the
occurrence of cerebral infarction. Significantly elevated SUA levels have been associated with a better prognosis in
patients with cerebral infarction; however, the results from some studies on the relationship between SUA and the
prognosis of patients with cerebral infarction remain controversial.
Methods: We analyzed the relationship between SUA and clinical prognosis of 585 young Chinese adults with
acute ischemic stroke as determined by the modified Rankin Scale at discharge. Using multivariate logistic
regression modeling, we explore the relationship between SUA levels and patient’s clinical prognosis.
Results: Lower SUA levels at time of admission were observed more frequently in the lowest quintile for patients
with severe stroke (P = 0.02). Patients with cerebral infarction patients caused by small-vessel blockage had higher
SUA concentrations (P = 0.01) and the lower mRS scores (P < 0.01) were observed in, while the lowest SUA
concentrations and the highest mRS scores were seen in patients with cardiogenic cerebral infarction patients.
Logistic regression analysis adjusted for confounders confirmed the following independent predictors for young
cerebral infarction: uric acid (-0.003: 95%CI 0.994 to 0.999) and platelet (0.004, 95%CI 0.993 to 0.996).
Conclusion: Elevated SUA is an independent predictor for good clinical outcome of acute cerebral infarction
among young adults.
Background
Stroke in young adults is an important cause of lifelong
disability. Thus it is very important to study the patho-
genesis and prognosis of young patients with cerebral
infarction. Conventional risk factors for arterial throm-
bosis at young age, such as gender, smoking, diabetes
mellitus, obesity and hypercholesterolemia do not fully
explain the cerebrovascular risk, Therefore additional
factors may exist which contribute to the likelihood of
developing arterial thrombosis in young adults. Studies
have shown that elevated SUA can increase the risk of
hypertension, diabetes, dyslipidemia, obesity, and renal
failure [1-3].
More recent researchers have established a relation-
ship between elevated SUA and vascular events (mainly
cardiovascular disease), and it is believed that elevated
serum uric acid levels could increase the morbidity and
mortality from cerebral infarction [4-7]. However, other
large-scale studies have found that SUA is a powerful
free radical scavenger in humans, and SUA concentra-
tion in normal adults is almost 10-folder higher than
that of other antioxidants [8]. Cerebral infarction initi-
ates a complicated cascade of metabolic events and pro-
duce lots of free-radical that mediated oxidative damage
in the central nervous system [9].
Studies with experimental cerebral ischemia have
demonstrated the neuroprotective effects of SUA. SUA
could scavenge superoxide, hydroxyl radical, oxygen,
* Correspondence: gzyxysjk@yahoo.com.cn
1Key Laboratory of Neurogenetics and Channelopathies of Guangdong
Province and The Ministry of Education of China, Institute of Neuroscience
and The Second Affiliated Hospital of GuangZhou Medical University, 250#
Changgang east Road, GuangZhou, 510260 Guangdong Province, China
Full list of author information is available at the end of the article
Zhang et al. BMC Neurology 2010, 10:82
http://www.biomedcentral.com/1471-2377/10/82
© 2010 Zhang et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.and chelate transition metals. Beside its ability to react
with potent oxidants, SUA is also able to almost com-
pletely prevent the inactivation of SOD3 by H2O2
[10,11]. Clinical studies with confounders well-con-
trolled demonstrated that higher levels of SUA in stroke
patients on admission predicted better prognosis [12].
These contradictory findings may be related to experi-
mental designs and condition definitions. In other
words, could higher levels of SUA at admission predict
better outcomes in stroke patients? We try to answer
this question in a large series of young patients with
acute ischemic stroke.
Methods
All consecutive patients between the ages of 18 and 45
years with first-ever cerebral infarction during 2001-
2009 were recruited to participate in the study. The
Second Affiliated Hospital of GuangZhou Medical Uni-
versity is the largest city hospital, covering about
250 million people, was the main center for the study.
Another group of patients from the Second Affiliated
Hospital of Guangzhou Medicine University, Guangz-
hou, in China were consecutively enrolled in the study.
All patients were Chinese. All patients were admitted
within 48 hours of experiencing a new focal or global
neurological event. Brain imaging (either CT or MRI)
was performed routinely within 24 to 48 hours after
admission. We excluded patients with cerebral infarction
from other intracranial-related diseases such as subar-
achnoid hemorrhage, sinus venous thrombosis, or severe
head trauma.
Cerebral infarctions were classified according to the
TOAST system [13]. The modified Rankin Scale (mRS)
was available and utilized in 585 patients. The mRS
score at discharge was classified as independent (score 0
to 2) or dependent/dead (score 3 to 6).
At baseline, demographic data (age and sex) and his-
tory of conventional vascular risk factors (hypertension,
diabetes mellitus, atrial fibrillation, hyperlipidemia,
smoking habit, alcohol abuse) were obtained. Routine
blood and biochemical tests, ECG, and a baseline brain
CT/MRI scan were performed in all patients at admis-
sion. Laboratory investigations for vascular risk factors,
duplex sonography of the carotid and vertebral arteries,
and a thorough cardiac investigation were all taken. All
patients received treatment according to current guide-
lines, but none of them underwent thrombolysis or sur-
gical treatment.
All patients had given informed consent to participate
in the study. Permission for the study was obtained
from the local ethics committees. The 330 healthy
patient control groups come from hospital staffs, and
exclusion factors in the control group included a history
of stroke, dementia, Parkinson’sd i s e a s e ,m u l t i p l e
sclerosis, renal failure, severe traumatic brain injury,
brain tumor and other diseases affecting the SUA level.
These people had never taken drugs that could poten-
tially confound SUA concentration.
UA measurement
All blood samples were collected on the first day of
admission under fasting state, and SUA was measured
in accordance with standard detection methods in the
hospital biochemistry department of this hospital. The
specific method: Non-fasting blood was collected and
centrifuged. Within 30 minutes, the blood was centri-
fuged for 10 minutes at 3000 rotations per minute at
room temperature. Subsequently, SUA activity was
determined with a Kone Diagnostica reagent kit and a
Kone autoanalyzer. External quality control program
showed that the interassay coefficient of variation was
lower than 4.1%.
Statistical Analyses
Statistical analyses were performed with the c
2 test for
binary and categorical data and the Mann-Whitney U
test for continuous variables. The severity of the cere-
bral infarction was classified as mild (mRS score 0 to 2:
absent or mild neurological symptoms) and moderate/
severe (mRS score 3 to 6: moderate or severe disability/
death) according to the mRS score at discharge [14].
Multivariate analysis was performed by binary logistic
regression analysis, which allows adjustment for con-
founding factors. All variables have an inclusion criter-
ion of P < 0.10 that were at least weakly associated with
stroke severity. In the binary logistic regression model,
the history of TIA/stroke, diabetes mellitus, atrial fibril-
lation, serum fibrinogen, hypertriglyceridemia, hypercho-
lesterolemia, TOAST type, serum triglyceride and
cholesterol levels, serum platelet and PDW levels, serum
leukocyte, SUA and glucose levels were used to examine
the effect of these variables in the prediction of group
status (mRS score 0 to 2, mRS score 3 to 6). The ana-
lyses were undertaken with the SPSS (version 11.1) soft-
ware package.
Results
Clinical Characteristics
A total of 426 young patients had better prognosis at
discharge (mRS 0-2), while 159 young patients who had
a worse prognosis (mRS 3-6). As shown in Table 1,
those patients with poor outcomes were more likely to
have risk factors such as diabetes, hypertriglyceridemia,
metabolic syndrome presence, moyamoya/cerebral vas-
cular malformation more frequently. furthermore, they
rarely suffered from history of stroke/TIA.
Blood tests revealed that in those patients with worse
prognosis, the number of white blood cells, serum
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admission significantly increased, in contrast, SUA and
platelet count significantly decreased.
The admission SUA levels were usually in the lowest
quintile for patients with worse prognosis (P = 0.02,
Table 2).
The relationship between Admission SUA Concentra-
tion and Demographics and Risk Factors
As shown in table 3, there were significantly increased
SUA concentration in male patients with hypertension,
current smokers, hypertriglyceridemia and
hypercholesterolemia.
In table 4, patients with cerebral infarction caused by
small artery occlusion had the highest SUA concentra-
tions and the lowest mRS score. In contrast, patients
with cerebral infarction from cardiogenic causes had the
lower SUA concentrations and the highest mRS scores.
Table 1 Baseline Characteristics of Study Population in Relation to Stroke Severity According to mRS Score at
discharge
Characteristic MRS 0-2
(n = 426)
MRS 3-6
(n = 159)
P
Male/Female 283/143 107/52 0.844
Age, y 39.6 ± 6.5 39.2 ± 6.5 0.504
Current cigarette smoking, n (%) 120 (28.2%) 48 (30.2%) 0.631
Current Alcohol drinking, n (%) 78 (18.3%) 30 (18.9%) 0.877
Previous stroke/TIA, n (%) 56 (13.1%) 9 (5.7%) 0.010
Atrial fibrillation, n (%) 14 (3.3%) 24 (15.1%) 0.000
Hypertention, n (%) 190 (44.6%) 76 (47.8%) 0.49
Diabetes at baseline, n (%) 70 (16.4%) 43 (27.0%) 0.004
Hypercholesterolemia, n (%) 137 (32.2%) 41 (257%) 0.136
Hypertriglyceridemia, n (%) 161 (37.8%) 43 (27.0%) 0.015
Metabolic syndrome presence, n (%) 21 (4.9%) 10 (6.3%) 0.003
Family history of stroke, n (%) 19 (4.5%) 13 (8.2%) 0.079
Moyamoya/Cerebral vascular malformation, n (%) 14 (3.3%) 13 (8.2%) 0.012
TOAST classification 0.000
a. Large artery, n (%) 127 (29.8%) 84 (52.8%)
b. Small artery, n (%) 226 (53.1%) 19 (12.0%)
c. Cardioembolism, n (%) 21 (4.9%) 31 (19.5%)
d. Other cause, n (%) 52 (12.2%) 25 (15.7%)
nonfasting glucose, mmol/L 5.65 ± 2.44 6.44 ± 3.03 0.001
Platelet distribution width, fL 12.7 ± 4.6 12.1 ± 3.0 0.072
Platelet count, ×10
9/L 237.8 ± 80.0 224.9 ± 82.9 0.019
White cell count, ×10
9/L 8.6 ± 5.6 10.0 ± 4.2 0.000
Mean platelet volume, fl 10.2 ± 1.4 10.2 ± 1.5 0.85
UA, mmol/L 326.2 ± 103.4 295.7 ± 111.2 0.002
Triglyceride (TG), mmol/L 1.7 ± 1.4 1.6 ± 1.6 0.382
Cholesterol (CHOL), mmol/L 4.7 ± 1.1 4.9 ± 1.1 0.017
Fibrinogen, g/l 1.7 ± 0.4 2.7 ± 1.7 0.000
Table 2 Association Between UA and Stroke Severity
According to mRS Score at discharge
UA Quintiles mRS 0-2
n = 426
mRS 3-6
n = 159
P
1 (76-227 mmol/L) 73 (17%) 45(28%) 0.019
2 (228-285 mmol/L) 90(21%) 29(18%)
3 (286-336 mmol/L) 80(19%) 34(22%)
4 (337-403 mmol/L) 91(21%) 29(18%)
5(404-673 mmol/L) 92(22%) 22(13%)
Cut points for quintiles are 227 mmol/L, 285 mmol/L, 336 mmol/L,403 mmol/L.
Table 3 Uric Acid Concentration on Admission in
different clinical Demographics
Variable yes No P
Female sex 273.0 ± 96.0 340.3 ± 104.2 0.000
Hypertension 334.7 ± 110.9 304.0 ± 100.4 0.001
Current smoking 346.4 ± 95.7 306.5 ± 108.3 0.000
Current Alcohol drinking 313.6 ± 113.4 318.5 ± 103.1 0.660
diabetes 326.5 ± 106.0 317.1 ± 106.5 0.561
Prior TIA/stroke 320.0 ± 97.7 317.5 ± 107.8 0.638
Atrial fibrillation 321 ± 132.7 317.5 ± 105 0.767
Hypertriglyceridemia 343.6 ± 106.3 306.8 ± 105.3 0.000
Hypercholesterolemia 357.6 ± 102.6 297.9 ± 103.5 0.000
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clinical prognosis
As shown in table 5, stepwise multiple logistic regres-
sion analysis confirmed that the independent positive
relation between higher SUA levels on admission and
better prognosis at discharge. Moreover, higher serum
platelet levels on admission were also associated with
better prognosis (table 5). We also found a correlation
between higher serum fibrinogen and leukocyte, the
worse outcome. Meanwhile, diabetes is an independent
risk factor for young patients with cerebral infarction.
We have tried to determine a possible relationship
between SUA and patients prognosis 3 months after
cerebral infarction. However, the mRS after 3 months
was available in only 252 of the 585 patients (43%).
Finally, we compared the SUA levels in the control
healthy people and the cerebral infarction patients
(Table 6). The results showed that SUA levels in the
normal group were much higher than in young patients
with cerebral infarction (P = 0.023).
Discussion
Currently, the literature features controversial reports on
the relationship between SUA and cerebral infarction.
Many studies have found elevated SUA indicative of a
poor prognosis (dead or be in care) in vascular event
[7], especially elevated SUA increasing the incidence of
myocardial infarction and chronic renal failure [15].
Furthermore, large cohort studies have also shown that
SUA is an important independent risk factor for cardio-
vascular mortality and SUA may increase the risk of
cardiovascular events? [4,16-19].
Chamorro et al confirmed that patients with good
prognosis had higher SUA levels in the acute stage of
cerebral infarction classically [12]. In this study, the
results showed that young cerebral infarction patients
with better prognosis had elevated levels of SUA on
admission, and that patients within the lowest quintile
of SUA levels suffered from severer dysfunctions com-
pared with those patients within the highest quintile.
Waring et al also demonstrated that SUA reduced
exercise-induced oxidative stress in healthy adults. In
this study, we also compared SUA levels between age
and gender-matched control population, and young
patients with cerebral infarction, and found SUA con-
centrations in healthy controls is higher than in cerebral
infarction patients.
In our study, we demonstrated that the worst prog-
nosis was related with the lowest admission SUA levels
in cardiogenic cerebral infarction patients. thus, patients
with cerebral infarction caused by blockage of small
blood vessels had the better prognosis and higher SUA
levels on admission, which further illustrates that high
SUA level on admission is helpful for functional recov-
ery in young cerebral infarction patients.
In patients with acute stroke, the SUA concentra-
tions decreases significantly over time, and their
plasma antioxidant capacity is inversely related to the
volume of cerebral infarction and the severity of neu-
rological impairment [20]. Neurological impairment at
stroke onset and final infarction size at follow-up are
inversely related with the concentration of SUA [12].
Although the SUA level at stroke onset is associated
with the presence and duration of atherosclerotic risk
factors and the severity of atherosclerotic disease, the
odds of good clinical outcome after the ischemic insult
increases 12% for each milligram per deciliter increase
of SUA [12]. Our study further suggests that SUA
confers significant protection as an antioxidant and
anti-free radical in young acute cerebral infarction
patients, ant that SUA administration may become a
new target for neuroprotection in cerebral infarction
patients. Waring et al had administrated the UA in
healthy control and observed a significant increase in
the free-radical scavenging capacity of serum, using
two methodologically distinct antioxidant assays. The
effect of SUA was substantially greater than that of
vitamin C [21].
Why is SUA generally lower in the cerebral infarction
patients with poor prognosis? Experimental data can
Table 4 UA concentrations in different stroke subtype
TOAST All ptients
n = 585
mRS
a. Large artery 319.5 ± 108.5 2.1 ± 1.4
b. Small artery 333.6 ± 98.3 0.9 ± 0.9
c. Cardioembolism 313.6 ± 133.4 2.7 ± 1.7
d. Other cause 293.8 ± 106.2 2.0 ± 1.6
P 0.01 0.000
Table 5 Independent Predictors of Functional Outcome at
Hospital Discharge
OR (95% CI) b PO R
UA 0.994-0.999 -0.003 0.006 0.997
PLT 0.993-0.999 -0.004 0.020 0.996
Fibrillation 1.691-11.389 1.479 0.002 4.389
Diabetes 1.193-3.674 0.739 0.010 2.094
Leukocyte 1.078-1.257 0.152 0.000 1.164
Table 6 UA concentrations in normal control and all
patients
Sex(M/F) Age (years) UA (mmol/l)
Healthy 231/99 38.8 ± 7.0 328.3 ± 78.8
All patients 390/195 39.5 ± 6.4 317.7 ± 106.9
P 0.3 0.474 0.023
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eral ways: first, ischemic neuronal damage studies have
shown that addition of physiological concentrations of
UA protects hypothalamic neurons from excitotoxic and
metabolic injury in vitro [22]; second, normal SUA con-
centrations in human plasma was able to almost com-
pletely prevent the inactivation of SOD3 by H2O2. Some
studies indicate that local SUA concentrations increase
during acute ischemic events, which might be a com-
pensatory mechanism that inhibited the increase of free
radical activity [23]; thirdly, the elevated SUA concentra-
tions also reduce oxidative stress caused by acute physi-
cal exercise, as reflected by plasma 8-iso-
PGF2aconcentrations [24]. In our studies, we also found
that higher admission platelet concentration resulted in
better prognosis. This discovery is very significant, how-
ever, because this was not the main aim of the study,
we cannot exclude the prognostic influence of these fac-
tors. In our future work, we will focus on more mean-
ingful clinical indicators.
With regards to the time of SUA quantification,
we made reference to the measurement of Chamorro A
et al [12]; we measured the SUA on admission in order
to avoid any interference by the intensity of fluid repla-
cement or the heterogeneous administration of medical
therapies.
In our analysis, the interfering factors such as creati-
nine levels, electrolyte levels, and the factor of with or
without kidney disease were considered. All selected
patients were admitted to hospital within 72 hours in
order to remove the impact of time of onset as well as
bed rest on the SUA level.
However, two limitations existed which should be
taken into account when assessing the results. First, sub-
group analysis has been limited by the relatively small
sample size, which might also have caused the non-sig-
nificance of some statistical tests. Second, these patients
were not followed up, so that the long-term prognostic
significance of early SUA measurements could not be
documented, although not included among the goals at
the onset of this investigation.
Conclusion
In this study, we described the relationship between
admission SUA and clinical prognosis of young cerebral
infarction patients using a validated outcome scale in a
large evaluation. Despite some limitations, our study still
supports that SUA play a protective role in young cere-
bral infarction patients through its antioxidant capacity.
Further research is needed at both the scientific and
clinical levels before routine treatment of SUA can be
recommended.
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